[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354967-105":59,"doc-detail-354967-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","choosing-the-right-animal-model-for-sarcoma-research-review","Choosing the right animal model for sarcoma research - Review","","Sarcomas include over 100 mesenchymal malignancies marked by extreme genomic heterogeneity, from fusion-driven pediatric tumors to highly unstable adult leiomyosarcomas, which shapes growth, metastasis, and treatment response. Effective preclinical animal models must mirror both tumor molecular features and the microenvironment, including dynamic interactions with the host immune system. Because sarcoma-specific model resources are limited, the review compares syngeneic, chemically induced, CDX, PDX, humanised PDX, and zebrafish models, highlighting use cases, advantages, and limitations while excluding genetically engineered model development.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/choosing-the-right-animal-model-for-sarcoma-research-review/354967/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/choosing-the-right-animal-model-for-sarcoma-research-review/354967.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is choosing the right animal model critical for sarcoma research?","Question",{"text":113,"@type":114},"Sarcomas show extreme genomic heterogeneity that influences tumor behavior, metastasis, and therapy response. Models must capture not only molecular traits but also microenvironment and immune interactions to reflect real biology.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What limitations do non-animal preclinical platforms have in sarcoma studies?",{"text":118,"@type":114},"2D monolayers, 3D spheroids, organoids, and organotypic slices enable mechanistic work and screening, but they lack perfused vasculature, intact stroma, and an adaptive immune system. This restricts studies of exposure-response, metastatic tropism, and host–tumor crosstalk.",{"name":120,"@type":111,"acceptedAnswer":121},"Which types of animal models are reviewed and what do they help address?",{"text":122,"@type":114},"The review discusses syngeneic models, chemically induced models, cell-derived xenografts (CDX), patient-derived xenografts (PDX), humanised PDX (huPDX), and zebrafish models. Each supports sarcoma-specific use cases while carrying distinct advantages and limitations.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354967,1790528236,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Cellular and Molecular Life Sciences (2026) 83:73  \n[https://doi.org/10.1007/s00018-025-06013-z](https://doi.org/10.1007/s00018-025-06013-z) Cellular and Molecular Life Sciences  \nREVIEW  \nChoosing the right animal model for sarcoma research  \nPiotr Remiszewski1,2 · Eryk Siedlecki1,2 · Marlena Wełniak-Kamińska3 · Michał Mikula4 · Anna Czarnecka1,5,6  \nReceived: 7 June 2025 / Revised: 8 November 2025 / Accepted: 5 December 2025 © The Author(s) 2026  \nAbstract  \nSarcomas comprise over 100 mesenchymal malignancies characterised by extreme genomic heterogeneity, ranging from fusion-driven paediatric tumours to highly unstable adult leiomyosarcomas. This genetic complexity shapes tumour behaviour, influences growth and metastasis, and determines how patients respond to therapy. Accurate animal models must reflect not only the molecular characteristics of these tumours, but also their microenvironment and dynamic interaction with the host immune system. The diversity of this group of cancers presents different challenges for animal model selection, particularly as sarcoma-specific resources are very limited. Therefore, we have reviewed in detail several types of models, including: syngeneic (e.g., MCA205 and KRIMS series), chemically induced (e.g., MCA, DMBA), cell-derived xenografts (CDX; e.g., KCS8 and KCS9 osteosarcoma lines), patient-derived xenograft (PDX; e.g., pleomorphic leiomyosarcoma and GIST models), including humanised PDX (huPDX; e.g. HuNOG-EXL), and zebrafish (e.g. tp53M214KPNSTand EWS-FLI1 transgenics) - to illustrate their sarcoma-specific use cases and discuss their advantages and limitations. Genetically engineered models and their development are not a subject of this review, as they represent a very broad subject independently and are discussed elsewhere.  \n􀀍  \n1  \n2  \n3  \nAnna Czarnecka  \n[anna.czarnecka@gmail.com](anna.czarnecka@gmail.com)  \nDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland  \nMedical Faculty, Medical University of Warsaw, Warsaw, Poland  \nSmall Animal Magnetic Resonance Imaging Laboratory, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland  \n4 Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw 02-781, Poland  \n5 Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland  \n6 Outpatient Chemotherapy Department, Maria SklodowskaCurie National Research Institute of Oncology, Roentgena 5 St, Warsaw 02-781, Poland  \n1 3  \nGraphical abstract  \nKeywords Sarcoma · Animal modelling · Preclinical models · CDX · PDX  \nIntroduction  \nSome sarcomas are driven by simple translocations (e.g. EWS-FLI1 in Ewing’s Sarcoma), others by complex karyotypic instability or recurrent mutations, with corresponding differences translate into variable biology - including immune-microenvironment profiles - across subtypes [1] . Clinically, this heterogeneity is reflected in generally poor outcomes: The 5-year overall survival (OS) for Soft Tissue Sarcomas (STS) is 90% for stage I, 81% for stage II, and 56% for stage III [2], with the influence of multiple factors beyond TNM stage, including surgical margins, age, anatomic location, and histological factors, especially grade and subtype [3, 4] . Studies have shown that median OS after first documentation of metastatic disease is approximately 24 months, with 1-, 2-and 5-year OS rates of 70%, 49.9% and 24.8%, respectively [5] . Therefore, there is the urgent need for further therapies development. Adequately-chosen models improve the fidelity of preclinical testing, allowing  \nscientists to distinguish between drugs that are truly promising and those that are unlikely to succeed in the clinic. Better animal models streamline the drug development pipeline, preventing costly failures and accelerating the introduction of effective therapies to patients in need","cbCaidcXyn1EQTEf","https://ap.wps.com/l/cbCaidcXyn1EQTEf","pdf",2540033,27,"English","# Introduction\n## Heterogeneity and clinical outcomes\n## Rationale for model selection\n## Preclinical platforms and their limits\n## Benefits and constraints of animal models","[{\"question\":\"Why is choosing the right animal model critical for sarcoma research?\",\"answer\":\"Sarcomas show extreme genomic heterogeneity that influences tumor behavior, metastasis, and therapy response. Models must capture not only molecular traits but also microenvironment and immune interactions to reflect real biology.\"},{\"question\":\"What limitations do non-animal preclinical platforms have in sarcoma studies?\",\"answer\":\"2D monolayers, 3D spheroids, organoids, and organotypic slices enable mechanistic work and screening, but they lack perfused vasculature, intact stroma, and an adaptive immune system. This restricts studies of exposure-response, metastatic tropism, and host–tumor crosstalk.\"},{\"question\":\"Which types of animal models are reviewed and what do they help address?\",\"answer\":\"The review discusses syngeneic models, chemically induced models, cell-derived xenografts (CDX), patient-derived xenografts (PDX), humanised PDX (huPDX), and zebrafish models. Each supports sarcoma-specific use cases while carrying distinct advantages and limitations.\"}]","Choosing the right animal model for sarcoma research - Review | PDF",1790115140,68,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a80f3b80f568e274ae4cdd4ff5f2a8c.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a0b02579093ed9c95fe12fda0810c97.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97a85a307a8f07ba51f346b980616a8b.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0cc718c978a298c006569b8713a1382e.webp",980,1301]